The Cardiac Amyloidosis Revolution: How ATTR Therapies Are Rewriting Heart Failure Treatment in 2026
For decades, cardiac amyloidosis was a diagnosis cardiologists whispered and patients rarely heard. In 2026, tafamidis, acoramidis, RNA silencers, and a CRISPR gene editing therapy are transforming ATTR care and…
